**CS5560 Knowledge Discovery Management**

**Lab Assignment 3**

**Lab Submission before November 9th 2018 (11:59 PM).**

Submit a short lab report including screenshots and data description to Turnitin . Post your GitHub URL with Source Code (No wiki) through Lab 3 form at https://goo.gl/forms/MP2n7LQGmm2atsZo2

1. ***Report Data Statistics using tables, figures or graphs from Earlier Lab Assignments***

***TFIDF***

***(Th17 cells,9.40550102865391)***

***(and progression,9.40550102865391)***

***(murine models,9.40550102865391)***

***(that EphB3,7.054125771490433)***

***(SF3B1, SRSF2,7.054125771490433)***

***(cells in,7.054125771490433)***

***(and U2AF1,7.054125771490433)***

***(in cattle,7.054125771490433)***

***(GC cells,7.054125771490433)***

***(SRSF2 and,7.054125771490433)***

***(following transmission,7.054125771490433)***

***(transmission to,7.054125771490433)***

***(progression of,7.054125771490433)***

***(models of,5.8377304471659395)***

***(development and,5.8377304471659395)***

***(EphB3 was,4.702750514326955)***

***(forms of,4.702750514326955)***

***(of SF3B1,,4.702750514326955)***

***(cells may,4.702750514326955)***

***(compared to,4.702750514326955)***

***(of GC,4.702750514326955)***

***(nucleus and,4.702750514326955)***

***(MGD is,4.702750514326955)***

***(highest values,4.702750514326955)***

***(spliceosomal mutations,4.702750514326955)***

***(and tryptic,4.702750514326955)***

***(of Th17,4.702750514326955)***

***(increases in,4.702750514326955)***

***(mass spectrometry,4.702750514326955)***

***(of bovine,4.702750514326955)***

***(were infected,4.702750514326955)***

***(of atypical,4.702750514326955)***

***(include the,4.702750514326955)***

***(used to,4.702750514326955)***

***(the molecular,4.702750514326955)***

***(were found,4.702750514326955)***

***(characterisation of,4.702750514326955)***

***(transmission in,4.702750514326955)***

***(atypical BSE,4.702750514326955)***

***(For L-BSE,4.702750514326955)***

***(genetic modification,4.702750514326955)***

***(and mouse,4.702750514326955)***

***(to Tg,4.702750514326955)***

***(to other,4.702750514326955)***

***(of EphB3,4.702750514326955)***

***(with cervical,4.702750514326955)***

***(with highest,4.702750514326955)***

***(values at,4.702750514326955)***

***(was used,4.702750514326955)***

***(T cell,4.702750514326955)***

***TF\_IDF\_Lemmas***

***(ephb3,23.513752571634775)***

***(gc,21.1623773144713)***

***(hpv,21.1623773144713)***

***(sma,11.756876285817388)***

***(th17,11.756876285817388)***

***(rabbit,11.756876285817388)***

***(circadian,11.756876285817388)***

***(molecular,11.756876285817388)***

***(glioblastoma,11.675460894331879)***

***(cattle,11.675460894331879)***

***(progression,9.40550102865391)***

***(tumor,9.40550102865391)***

***(murine,9.40550102865391)***

***(branaplam,9.40550102865391)***

***(prpsc,9.40550102865391)***

***(follow,9.40550102865391)***

***(prion,9.40550102865391)***

***(mds,9.40550102865391)***

***(%,9.40550102865391)***

***(tg,9.40550102865391)***

***(MGD,9.40550102865391)***

***(ang-cp,7.783640596221253)***

***(response,7.783640596221253)***

***(cervical,7.783640596221253)***

***(classical,7.054125771490433)***

***(srsf2,7.054125771490433)***

***(peptide,7.054125771490433)***

***(NAGLU,7.054125771490433)***

***(BSE,7.054125771490433)***

***(bovine,7.054125771490433)***

***(pressure,7.054125771490433)***

***(fusion,7.054125771490433)***

***(∼,7.054125771490433)***

***(lysosomal,7.054125771490433)***

***(u2af1,7.054125771490433)***

***(sf3b1,7.054125771490433)***

***(atypical,7.054125771490433)***

***(sheep,7.054125771490433)***

***(modification,7.054125771490433)***

***(nucleus,7.054125771490433)***

***(mediate,7.054125771490433)***

***(n-taap,7.054125771490433)***

***(smn2,7.054125771490433)***

***(bse,7.054125771490433)***

***(rhythm,7.054125771490433)***

***(mds/mpn,7.054125771490433)***

***(transmission,6.63291230641413)***

***(form,5.8377304471659395)***

***(siplk1,5.8377304471659395)***

***(expression,5.740338101157291)***

***Total Medical Words: 1310***

***Words Count***

***inflammatory breast cancer 2***

***b2GPI 1***

***DNA methyltransferase 2***

***participants 1***

***neurogenic inflammation 1***

***Myelodysplastic syndromes 3***

***E. coli 2***

***STAT5b 2***

***DNMT 1***

***Gardnerella vaginalis 1***

***LMI070 2***

***a-N-acetylglucosaminidase 4***

***anthracycline 1***

***metastasis 3***

***Mdv1 1***

***Cancer Genome Atlas 1***

***Fms Like Tyrosine Kinase 3 1***

***Glioblastoma Multiforme 1***

***Fms like tyrosine kinase 3 1***

***heart disease 1***

***infection of the genital tract with HR-HPV triggers chronic inflammation 1***

***polyethylenimine 1***

***TPO 2***

***squamous intraepithelial lesions and HPV infections 1***

***type of brain disease or injury 1***

***cancers 3***

***fungal 2***

***SMN 4***

***premalignant cervical lesions 1***

***PER1 3***

***beta-2-glycoprotein I 1***

***thrombosis 1***

***TSS 2***

***survival motor neuron-2 2***

***bacteria 2***

***FLT3 2***

***person 2***

***Mouse 5***

***schizophrenia 4***

***neuromuscular disorder 2***

***Gene 126***

***cervical cancer 1***

***Alzheimer's disease 1***

***IL15Ra 2***

***meningoencephalitis 1***

***SOX2 4***

***splenic marginal zone lymphoma 3***

***humans 7***

***donor 4***

***immunodeficiency 2***

***BCL-xL 4***

***senile plaque 1***

***Tuberous sclerosis complex 2***

***glioblastoma 26***

***L-MYC 4***

***vimentin 6***

***Men 1***

***AIDS 1***

***aglycosyl 2***

***Temozolomide 2***

***MDS/MPN 9***

***IgG1 3***

***epidemic 1***

***Thiram 1***

***Rabbits 6***

***graft-vs.-host disease 1***

***Rabbit 3***

***S. aureus 1***

***Sanfilippo syndrome type B 4***

***cyclophosphamide 1***

***P. aeruginosa 1***

***sheep 4***

***autoimmunity 2***

***vision loss 1***

***GC 27***

***MDS 12***

***Disease 34***

***hematological malignancies 1***

***infants 2***

***male 3***

***Human 2***

***endemic diarrheal disease 1***

***bEnd.3 5***

***patients 42***

***Women 1***

***VEGF 1***

***Zebrafish 1***

***autoimmune disease 5***

***rs10770141 3***

***LRP-1 5***

***damage to the retina 1***

***SID 4***

***leukemia 1***

***tumor 12***

***rs1799732 1***

***KLF4 4***

***Rhodesian human African trypanosomiasis 1***

***Tyrosine 1***

***bendamustine 2***

***RA 10***

***metastatic disease 1***

***P-glycoprotein 1***

***cancer 7***

***inflammatory disorders 1***

***CIN3 lesions 1***

***substance P 1***

***IMEDEAi005-B 12***

***flavonoid 1***

***infections 1***

***BD2 11***

***BD3 1***

***TMZ 8***

***kidney stone 1***

***febrile neutropenia 1***

***rheumatoid arthritis 4***

***primary immunodeficiencies 2***

***Aldox 8***

***Sanfilippo syndrome 4***

***Chemical 15***

***CGRP 3***

***16H5 1***

***cluster of differentiation 1***

***infection 2***

***Pro358Leu 4***

***ACPA 2***

***schizoaffective disorder 2***

***AD 2***

***CD4 1***

***S. pneumoniae 1***

***Spinal muscular atrophy 2***

***death 11***

***BSE 6***

***antipsychotic-induced dopamine supersensitivity psychosis 1***

***5T4 6***

***embryos 1***

***STAT 1 2***

***UCC 3***

***TRS 2***

***Bacteria 1***

***cardiovascular disease 3***

***African trypanosomiasis 1***

***pain 1***

***P-gp 2***

***Glioblastoma 5***

***P358L 8***

***interleukin 17 1***

***IL15RA 2***

***yeast 4***

***murine 12***

***heparin sulphate 4***

***bacterial 2***

***mammalian 1***

***human papillomavirus 1***

***polyamine cationic liposomes 2***

***transmissible spongiform encephalopathy 2***

***Toxicity 2***

***invasive breast cancer 1***

***PIDs 2***

***pruritus 1***

***IL17 2***

***PCL 1***

***uterine cervical cancer 1***

***IgG 1***

***brain infection 1***

***Mutation 12***

***Diabetic retinopathy 1***

***IBC 9***

***lysosomal storage disease 4***

***bacterial infection 1***

***rs4680 3***

***GVHD 3***

***lymphoma 1***

***amphiregulin 2***

***rapamycin 1***

***Danio rerio 1***

***DRD2 3***

***Branaplam 2***

***susceptible-infected-diseased 1***

***LSD 8***

***Dox 2***

***treatment-resistant schizophrenia 1***

***STAT1 2***

***lichen planopilaris 1***

***SMN1 2***

***Extranodal Lymphoma 1***

***anoxia 1***

***zebrafish 1***

***mice 22***

***cholesterol 3***

***vector-borne disease 1***

***Cryptococcus neoformans, a 1***

***EphB3 33***

***PrPSc 2***

***SMN2 8***

***loss of brain function 2***

***N 5***

***DR 6***

***SF3B1 9***

***dopamine 4***

***tyrosine 2***

***fungal disease 1***

***Citrulline 4***

***cervical dysplasia 2***

***C. neoformans 1***

***Bendamustine 1***

***U2AF1 9***

***citrulline 6***

***STAT3 2***

***mouse strain 2***

***AML 5***

***oxygen 2***

***diarrheal disease 2***

***polyethylene glycol 1***

***vagina 1***

***tumour 1***

***SRSF2 9***

***vascular endothelial growth factor 1***

***neurological disorders 4***

***corticosterone 3***

***neurofibrillary tangles 1***

***Aldoxorubicin 2***

***growth failure 2***

***CD 1***

***survival motor neuron 1 2***

***catechol 1***

***PEG 1***

***Cervical Intraepithelial Neoplasia 1***

***PLK1 10***

***HPV infections 2***

***colorectal cancer 1***

***GBM 4***

***G96 N 2***

***diabetes 1***

***breast cancer 2***

***Fungal 2***

***AREG 4***

***STAT1, 3 and 5b 2***

***Spinal Muscular Atrophy 2***

***Beta-2-Glycoprotein I 1***

***Deiodinase 3 1***

***TSC 4***

***Acute Myeloid Leukemia 1***

***incident kidney stones 2***

***APS 2***

***acute myeloid leukemia 1***

***PEI 1***

***CRC 1***

***mouse 17***

***Trypanosoma brucei 1***

***patient 7***

***autoimmune diseases 2***

***men 8***

***TSE 2***

***thyroid disruption 1***

***Human Papillomavirus 1***

***bovine 2***

***LIN28 4***

***b-defensin 2 1***

***fibrosing alopecia 2***

***SMA 8***

***toxicity 11***

***cattle 8***

***Transcriptional Start Site 2***

***IL-2 1***

***IgG2a 1***

***dysregulatory syndromes 2***

***diarrhea 1***

***Ser-Leu-Lys-Pro 1***

***OCT3/4 4***

***stomach cancer 1***

***lysosomal storage diseases 4***

***rabbits 6***

***glaucoma 6***

***brain ischemia 1***

***thiram 3***

***high blood pressure 3***

***polyphenol 1***

***rabbit 3***

***papillomavirus (HPV) infection 1***

***rs1800497 2***

***Diabetic Retinopathy 1***

***bacterial and fungal biota 1***

***Th1-type (IFN-y 1***

***LPP 5***

***E-cadherin 6***

***neurodegenerative disorder 4***

***branaplam 2***

***IL-6 1***

***Ai-DSP 9***

***Doxorubicin 1***

***AID 4***

***SMZL 4***

***Species 55***

***genetic disorders 2***

***MG glioblastoma 5***

***Th1 5***

***Lichen planopilaris 1***

***protamine 1***

***cyclic AMP 2***

***donors 1***

***viral infection 1***

***myelodysplastic/myeloproliferative neoplasms 3***

***human 40***

***NAGLU 16***

***Patients 2***

***EGFR 1***

***Neutropenia 1***

***infectious diseases 1***

***women 13***

***Mice 2***

***HPV 9***

***Cryptococcus neoformans 1***

***people 1***

***chronic mucocutaneous candidiasis 2***

***children 1***

***glioma 2***

***EZH2 6***

***orthotopic glioblastoma 5***

***Cryptococcus gattii 1***

***gastric cancer 6***

***Total nouns:1576***

***Total verbs:504***

***Total other:1577***

***Total Words: 5609***

***Words Count***

***extracted 1***

***uterine 2***

***paper 3***

***noncancerous 1***

***offer 2***

***goals 2***

***IFN-γ***

***1***

***intake 2***

***62 1***

***include 6***

***reality 2***

***N-TAAPs 1***

***modification 2***

***progressed 1***

***time-to-event 1***

***depletion 1***

***PEG-DI 2***

***been 27***

***over 1***

***improved 1***

***thrombosis 2***

***neuroprotection 6***

***flavonoid 2***

***application 4***

***simultaneously 3***

***APS 6***

***pharmacotherapy 2***

***neurodegenerative 3***

***genomes 1***

***compounds 2***

***technology 5***

***are 23***

***Addition 2***

***sites 2***

***host 5***

***efficacy 2***

***glycol 2***

***karyotype 3***

***widely 1***

***our 5***

***aid 1***

***form 3***

***G96 1***

***African 1***

***prolonged 1***

***infections 3***

***them 3***

***analogue 2***

***addition 6***

***recently 3***

***Variations 1***

***angiopep-2 4***

***induced 1***

***BSE 6***

***dynamics 1***

***antibody 2***

***comprehensive 1***

***aggressive 2***

***long 1***

***Recently 1***

***pharmacokinetic 2***

***proteins 2***

***day 2***

***contact 1***

***∼5% 1***

***serum 8***

***phenotype 1***

***enzyme 6***

***new 9***

***Branaplam 1***

***hampered 4***

***plaque 2***

***temperature 2***

***Despite 4***

***β2GPI 2***

***SRSF2 3***

***sexes 1***

***characteristics 3***

***treatment 13***

***siPLK1 12***

***suggest 2***

***T 3***

***severe 4***

***degree 1***

***animal 2***

***tangles 2***

***heterozygous 1***

***death 6***

***iPSCs 6***

***zone 4***

***neurons 2***

***low 4***

***citrulline-specific 1***

***sulphate 3***

***function 5***

***nutrition 6***

***inhibits 4***

***single 4***

***assess 2***

***near 1***

***resolution 1***

***graft 2***

***integration 3***

***IELSG 2***

***exert 2***

***histone 4***

***proteolytic 2***

***rate 2***

***morphology 3***

***developed 2***

***some 12***

***first 7***

***spatial 1***

***stabilizes 1***

***secretion 2***

***too 2***

***analysis 2***

***diarrheal 1***

***cancer 9***

***second 4***

***relationship 1***

***branaplam 3***

***Mucopolysaccharidosis 3***

***how 3***

***increasingly 2***

***into 9***

***TSC 6***

***implicated 1***

***PER1 1***

***focus 1***

***metaphysical 1***

***frog 2***

***Further 2***

***effectively 4***

***depend 1***

***overexpression 1***

***maintains 2***

***play 1***

***Program 2***

***front-line 2***

***E-cadherin 1***

***graft-vs.-leukemia 2***

***They 1***

***mimics 4***

***serious 2***

***modifying 1***

***species 2***

***molecular 5***

***dysplasia 1***

***diverse 1***

***mRNA 4***

***papillomavirus 2***

***disease 39***

***duration 1***

***other 13***

***unclear 1***

***disorder 4***

***Multiforme 2***

***SMN 2***

***BD2/3 2***

***clinic 2***

***PEGylation 6***

***systematically 2***

***between 14***

***believed 1***

***information 2***

***report 6***

***night 2***

***description 1***

***releasing 4***

***hybridization 1***

***lead 5***

***originated 1***

***"irreversible 1***

***rapamycin 2***

***synthesis 1***

***promoted 1***

***health 2***

***oxygen 1***

***interpretation 1***

***its 22***

***previously 2***

***produced 3***

***have 24***

***anti-tumor 1***

***highest 2***

***premalignant 1***

***express 4***

***several 5***

***MDS/MPN 3***

***affected 1***

***future.***

***1***

***testing 1***

***suckling 1***

***circadian 4***

***Doxorubicin 2***

***occurring 2***

***risks 2***

***eukaryotic 1***

***Our 2***

***TSS 1***

***annotations 2***

***varying 1***

***tool 1***

***Here 9***

***30% 2***

***free 3***

***promising 1***

***presents 4***

***rheumatoid 1***

***heavily 2***

***multiple 6***

***attending 2***

***ii 1***

***experimental 2***

***distinguished 1***

***vivo 5***

***balance 2***

***better 2***

***pathogenic 2***

***ANG-CP 16***

***selection 1***

***showed 7***

***emerges 4***

***short 2***

***favorable 1***

***Its 2***

***level 2***

***incidence 9***

***Relative 1***

***acute 2***

***variations 1***

***moderately 2***

***live 2***

***San 1***

***MDS 4***

***RNAi 16***

***using 4***

***databases 1***

***oncoprotein 4***

***Expression 2***

***Ser-Leu-Lys-Pro 2***

***discovery 2***

***OCT3/4 3***

***due 1***

***clinically 2***

***AML 4***

***dynamin-related 1***

***demonstrate 4***

***lymphoma/IELSG 2***

***family 1***

***diagnostic-therapeutic 2***

***ways 1***

***insight 2***

***suffers 2***

***fibroblast 3***

***Zambia 1***

***Cancer 3***

***site-specific 2***

***Michigan 2***

***technique 1***

***adopt 2***

***II 2***

***SMZL 4***

***exists 1***

***mass 2***

***occur 1***

***So 2***

***exploring 1***

***There 1***

***arm 2***

***general 3***

***region 3***

***transfection 4***

***changed 2***

***RA.***

***1***

***APS-IgG 2***

***still 4***

***low-risk 1***

***clearance 1***

***complex 5***

***MPSIIIB-iPSCs 3***

***constant 2***

***neoplasms 1***

***modulation 1***

***signal 1***

***BD2 1***

***mediation 1***

***transmission 9***

***deal 1***

***diet 1***

***Temozolomide 2***

***GC 8***

***TgEM16 1***

***can 19***

***discovered 2***

***full-length 1***

***oscillator 1***

***racial 2***

***Other 1***

***structures 2***

***anal 1***

***immunotherapy 2***

***delivery 1***

***infected 2***

***analyze 1***

***generation 3***

***variable 1***

***domain 2***

***Therefore 2***

***regulating 3***

***systems 2***

***drug 4***

***review 4***

***analyses 1***

***distribution 1***

***births 2***

***iPS 3***

***tract 1***

***interleukin 1***

***targeted 2***

***1/6000 2***

***repression 1***

***best 2***

***groups 1***

***UTILITY 3***

***fusion 3***

***significantly 14***

***expression 9***

***ABM 2***

***understanding 1***

***EM 2***

***cytoplasmic 4***

***change 3***

***Juan 1***

***two 6***

***high-dose 2***

***among 2***

***hypothesis 1***

***Circadian 1***

***STAT 1***

***proteinase 1***

***1/20000 2***

***fast 1***

***demonstrated 2***

***complexities 2***

***novel 2***

***Fms 2***

***school 1***

***muscular 1***

***factors 1***

***specificity 4***

***approach 3***

***polyethylene 2***

***Several 2***

***kDa 2***

***so 1***

***HSCT 8***

***Mucopolysaccharydosis 3***

***prove 1***

***young 1***

***SMA.***

***1***

***humans' 2***

***For 4***

***IIIB 6***

***rat 2***

***matrix 1***

***tested 4***

***gene 16***

***Rican 1***

***protection 4***

***analyzing 1***

***surgery 2***

***could 2***

***sequelae 2***

***All 1***

***result 2***

***affecting 1***

***silence 4***

***used 6***

***mutation 6***

***microRNA 2***

***less 4***

***determined 3***

***tubulin 4***

***human 21***

***expectation-maximization 1***

***deacetylases 2***

***different 5***

***FLT3 2***

***population 4***

***optimization 1***

***including 4***

***VR1020 1***

***diversity 1***

***constantly 1***

***activator 1***

***outlet 1***

***establish 1***

***but 3***

***affect 1***

***allogeneic 6***

***genes.***

***1***

***per 3***

***during 2***

***viable 2***

***transcriptional 1***

***germ 3***

***transcriptome 1***

***size 2***

***increases 2***

***cervix 2***

***disease-free 1***

***MGD; 1***

***carcinogenesis 1***

***DFS 1***

***absence 4***

***polymersomes 4***

***while 8***

***2003 1***

***ovinised 1***

***demographic 1***

***atrophy 1***

***within-household 1***

***natural 3***

***recapitulate 1***

***homeostasis 1***

***may 6***

***microbiota 1***

***transport 4***

***intraepithelial 1***

***morbidity 2***

***hallmarks 2***

***EPH 1***

***types 2***

***networks 2***

***technical 2***

***main 7***

***retain 2***

***physiological 1***

***Aldoxorubicin 2***

***anti-PLK1 4***

***multifaceted 2***

***breast 2***

***I 4***

***lumen 4***

***molecules 7***

***prions 1***

***Central 1***

***medical-scientific 1***

***plausible 1***

***pregnancy 2***

***inflammatory 2***

***motor 1***

***inducing 1***

***enhances 6***

***activities 3***

***cervicovaginal 2***

***toddlers 1***

***biota 1***

***agent 2***

***Aβ 6***

***innovative 2***

***infants 1***

***Transcriptional 1***

***syndrome 6***

***LSD 6***

***outcomes 1***

***allele 1***

***each 2***

***transition 1***

***DNMT 2***

***following 6***

***shp53 3***

***range 3***

***resides 1***

***pro-inflammatory 1***

***healthcare 4***

***conservative 2***

***splicing 2***

***innervation 1***

***multi-parameter 1***

***for 55***

***Much 2***

***cause 3***

***obtain 1***

***time 15***

***control 2***

***collaboration 1***

***biomarkers 1***

***targeting 4***

***internal 2***

***literature 1***

***profile 1***

***facilitating 1***

***5 1***

***While 2***

***was 16***

***community 1***

***creating 1***

***systemic 2***

***no 2***

***Italiana 2***

***ovine 1***

***prevalence 3***

***outgrowth 2***

***grew 2***

***area 1***

***mean 2***

***graft-vs.-host 2***

***combined 2***

***varied 1***

***anti-glioblastoma 4***

***intensive 2***

***rhythms 2***

***HDACs 4***

***extents 1***

***two-stage 2***

***Whilst 1***

***"epigenetic 2***

***invasion 1***

***model 6***

***made 1***

***Both 3***

***corticosterone 1***

***conservation 1***

***IL17 2***

***Cells 3***

***performing 1***

***Surveillance 2***

***quick 2***

***fat 2***

***therapy 12***

***in 131***

***described 2***

***kits 1***

***prodrug 2***

***reduces 2***

***diagnosis 3***

***inhibitors 6***

***∼44% 1***

***public 1***

***reactive 1***

***antiphospholipid 2***

***dodeca-neuropeptide 2***

***SMN1 1***

***skin 2***

***phenotyping 1***

***incurable 6***

***interface 1***

***derived 7***

***matter 1***

***shorter 2***

***genetically 1***

***effect 9***

***considering 2***

***Tg110 1***

***neuro-regeneration 2***

***Notably 4***

***binary 1***

***UCC 2***

***option 4***

***open-label 2***

***permeate 4***

***mediate 1***

***designed 4***

***microtubule 2***

***Modeling 1***

***tissue 1***

***DI 8***

***expertise 2***

***direct 1***

***bacteria 1***

***The 30***

***extended 1***

***than 2***

***β-defensin 1***

***having 2***

***received 2***

***myelodysplastic/myeloproliferative 1***

***payloads 4***

***cardiovascular 2***

***therapy" 2***

***lesions 4***

***resulting 1***

***84% 1***

***great 1***

***along 1***

***modality 4***

***thousands 1***

***study 11***

***anti-EGFR 2***

***target 3***

***called 1***

***pressure 3***

***the 254***

***deeper 1***

***production 6***

***degenerative 3***

***applied 1***

***fission 2***

***virulence 2***

***GVL 2***

***superior 2***

***efficient 2***

***RIKEN's 1***

***dominated 1***

***center 2***

***endemic 1***

***closely 1***

***objective 3***

***assay 2***

***clear 1***

***treated 3***

***amphibian 2***

***stem 3***

***strategies 1***

***7***

***cytokines 4***

***BD3 1***

***about 3***

***complete 2***

***complications 2***

***peptoid 10***

***improvements 1***

***protective 1***

***against 6***

***sympathetic 1***

***deficiency 3***

***features 1***

***strain 1***

***differentiation 1***

***lungs 2***

***9 1***

***suprachiasmatic 1***

***RNA 6***

***Committee 1***

***therapeutics 2***

***well-established 1***

***authorities 2***

***Splenectomy 2***

***methyltransferase 2***

***as; 4***

***1 2***

***living 1***

***endogenous 1***

***behavioral 1***

***efficiency 1***

***Association 2***

***curation 1***

***white 3***

***curative 2***

***traits 1***

***locomotion 1***

***economically 2***

***Study 4***

***Mouse 1***

***acid 1***

***plasmids 3***

***rituximab 2***

***polycomb 1***

***available 1***

***trypanosomiasis 1***

***Dox 2***

***more 5***

***contribute 1***

***classical 3***

***An 2***

***method 5***

***women; 2***

***aPL 4***

***Spinal 1***

***glaucoma 2***

***malignancies 2***

***ATP 1***

***manifestations 2***

***Puerto 1***

***olfactory 1***

***achieve 2***

***underlining 2***

***markers 4***

***comparative 1***

***characterized 6***

***particular 7***

***arises 2***

***corticosteroid 1***

***heparin 3***

***i 1***

***introitus 1***

***A 3***

***IgG 2***

***vaccination 1***

***LMI070 1***

***high-throughput 1***

***association 4***

***which 13***

***competent 1***

***biology 1***

***whether 2***

***peptide 5***

***spectrometry 2***

***summarize 1***

***NAGLU 12***

***compare 1***

***processes 1***

***output 1***

***mouse 7***

***Fis1 1***

***fungi 1***

***5T4 1***

***spliceosomal 2***

***differs 2***

***connected 2***

***studying 1***

***sets 1***

***absent 3***

***miRNA 6***

***healthy 2***

***immunogenicity 2***

***progress 1***

***rabbits 1***

***both 9***

***an 36***

***Multi 1***

***demonstrating 3***

***Mitochondria 1***

***0.03 3***

***ITD 2***

***Rabbits 2***

***regimen 2***

***tryptic 2***

***central 7***

***appear 1***

***first-line 2***

***α-N-acetylglucosaminidase 3***

***MPSIII 3***

***mice.***

***4***

***advances 1***

***ITS-2 1***

***consider 1***

***accumulates 3***

***race/ethnicity 2***

***organ 2***

***Standardized 1***

***around 2***

***explanation 1***

***ectopic 1***

***explored 1***

***co-infected 1***

***develop 2***

***accumulation 5***

***ones 1***

***Alzheimer's 2***

***provide 2***

***In 19***

***MPSIIIB 6***

***TMZ 2***

***neurofibrillary 2***

***marginal 4***

***manner 3***

***Gene 1***

***rHAT 2***

***cells 27***

***endpoint 2***

***Trypanosoma 1***

***gastric 1***

***binding 2***

***genetic 5***

***a 102***

***above 1***

***Fondazione 2***

***disparities 4***

***underlying 1***

***stimulation 1***

***actions 4***

***hematological 2***

***autosomal 3***

***biological 5***

***fed 1***

***DRPs 2***

***Control 1***

***subsequent 2***

***were 15***

***EMVS 1***

***fairly 2***

***Herein 1***

***proposes 1***

***patients' 2***

***response 8***

***Fifty-six 2***

***pathways 1***

***safe 5***

***immunosuppressive 1***

***greater 1***

***Simon's 2***

***bEnd.3 4***

***half-life 4***

***order 2***

***type 4***

***Rabbit 1***

***splenic 4***

***Linfomi 2***

***Bayesian 2***

***transgenic 1***

***responses 1***

***make 1***

***vitro 4***

***offering 2***

***Viewer 1***

***presented 1***

***humoral 1***

***burdensome 2***

***Western 1***

***deletion 1***

***SOX2 3***

***methylation 2***

***nervous 5***

***modulates 1***

***encourages 2***

***transplantation 2***

***mice 7***

***cholesterol 1***

***RESOURCE 9***

***pathogenesis 2***

***dysregulatory 1***

***Currently 1***

***preoptic 2***

***opposed 1***

***values 2***

***BBB 8***

***BCL-xL 3***

***naturally 2***

***thus 1***

***Nursing 1***

***senile 2***

***V4 1***

***warrants 1***

***scale 1***

***viral 1***

***reverse 1***

***collection 1***

***found 13***

***affects 2***

***syndromes 2***

***associated 3***

***ultimately 2***

***sometimes 2***

***polyphenol 2***

***transcription 1***

***differentiate 3***

***humans 3***

***colorectal 1***

***shows 5***

***frequent 4***

***reliability 1***

***We 13***

***amino 1***

***methods 1***

***profiles 2***

***primary 6***

***interference 4***

***true 2***

***directly 1***

***Cameroon 1***

***set 1***

***has 18***

***International 3***

***allows 1***

***resource 3***

***body 2***

***via 8***

***fine 1***

***vegetables 2***

***need 3***

***75 1***

***16S 1***

***families 2***

***As 1***

***neurite 2***

***Th17 5***

***treat 4***

***microwaves 2***

***three 3***

***PrPSc 4***

***17 1***

***quickly 4***

***often 3***

***knowledge 2***

***clock 2***

***spongiform 2***

***cleavage 2***

***abundances 1***

***organelles 1***

***HPV 9***

***blood 6***

***this 13***

***molecule 1***

***gold-standard 2***

***cell 9***

***results 1***

***codes 1***

***malfunctioning 3***

***epithelial-mesenchymal 1***

***patients 20***

***opinion 2***

***function" 1***

***adult 1***

***undergoes 1***

***trips 1***

***inherited 3***

***network 3***

***poor 4***

***high-risk 3***

***act 3***

***encouraging 2***

***provides 1***

***PrPres 2***

***Thus 2***

***Th1-type 1***

***DNMTs 2***

***pre-mRNA 2***

***DETAILS 3***

***When 3***

***arthritis 1***

***outcome 2***

***potential 6***

***crosses 2***

***Brain 2***

***involves 1***

***agents 12***

***antibodies 2***

***glioblastoma 20***

***Mice 1***

***autoimmune 2***

***TABLE 3***

***high 14***

***greatly 4***

***locomotor 1***

***states 2***

***currently 2***

***apply 1***

***therapeutic 8***

***P358L 6***

***one 4***

***transmissible 1***

***nontoxic 4***

***clinicopathological 1***

***increased 3***

***women 6***

***organism 1***

***reduced 1***

***conditional 1***

***mediates 1***

***biomarker 2***

***beneficial 2***

***from 27***

***interest 1***

***date 1***

***well 10***

***detected 2***

***BRISMA 2***

***adjacent 1***

***fully 3***

***PEG 2***

***alleles 1***

***alter 4***

***consistent 1***

***containing 3***

***lowest 1***

***oncofoetal 1***

***identification 1***

***effectiveness 2***

***will 1***

***trial 4***

***GBM 6***

***OriP/EBNA1-based 3***

***decreased 2***

***shortest 2***

***C3H/HeN 2***

***mutations 11***

***contributing 1***

***prognosis 6***

***disease-related 1***

***mutated 1***

***costs 2***

***vimentin 1***

***miRNAs 4***

***reduce 2***

***models 9***

***degradation 3***

***approaches 4***

***genes 2***

***span 2***

***SLKP 12***

***B 4***

***90 mg/m***

***2***

***screening 1***

***brain-targeting 8***

***kit 1***

***modulating 2***

***Fzo1 1***

***prolongs 4***

***we 20***

***This 8***

***tailored 2***

***enhanced 2***

***surveys.***

***1***

***homozygous 6***

***however 8***

***cyclophosphamide 1***

***intracranial 4***

***gene-immunoreactive 1***

***Mapping 1***

***years 3***

***characterisation 2***

***tissues 5***

***SPF10-LiPA25 1***

***murine 4***

***indicating 1***

***article 1***

***recombinant 4***

***cFOS- 1***

***recurrent 1***

***sought 1***

***LRP-1-mediated 4***

***MGD 3***

***as 53***

***proposed 2***

***applied.***

***1***

***duplication 2***

***survival 10***

***Start 1***

***owing 4***

***contributes 1***

***together 4***

***leading 1***

***devastating 3***

***hypothesized 2***

***non-viral 4***

***is 73***

***5T4-specific 1***

***summarizes 2***

***2011 3***

***PLK1 4***

***existence 4***

***same 1***

***impact 2***

***Myelodysplastic 1***

***sufficient 1***

***SMN2 3***

***shift 1***

***heart 2***

***Although 3***

***expressing 1***

***us 2***

***men 1***

***excellent 4***

***IBC 6***

***purified 1***

***effects 6***

***according 2***

***rabbit 1***

***polymerization 2***

***TCGA.***

***1***

***32D-FLT3***

***2***

***parameters 2***

***donor 3***

***transect 1***

***2014.***

***2***

***diagnosed 3***

***helper 1***

***decrease 2***

***bacterially-expressed 2***

***mainly 6***

***engineered 1***

***cruciferous 2***

***differences 1***

***machinery 1***

***Aldox 4***

***synthesize 2***

***ultrasound-guided 2***

***member 1***

***Extranodal 2***

***experiments 4***

***etiology 2***

***L-MYC 3***

***hematopoiesis 1***

***essential 1***

***peptides 2***

***neurological 3***

***occurrences 1***

***1 × 10***

***3***

***interfaces 1***

***binds 2***

***strains 1***

***cultural 1***

***advanced 2***

***Glioblastoma 6***

***potent 2***

***Dnm1 1***

***Since 3***

***TSE 2***

***prognostic 1***

***Results 2***

***mucosa 1***

***numerous 1***

***preclinical 2***

***However 8***

***episomal 3***

***prion 3***

***Group36 2***

***fighting 1***

***domestic 1***

***Africa 1***

***gland 1***

***documented 3***

***illnesses 1***

***chronic 1***

***interaction 1***

***protected 2***

***pathway 4***

***brain 13***

***km 1***

***layers 3***

***with 79***

***genital 1***

***data 2***

***2 2***

***therapeutics.***

***2***

***tumor-suppressor 1***

***UCC.***

***1***

***investigation 3***

***adaptive 1***

***relies 1***

***numbers 2***

***rhythm 1***

***options 6***

***percutaneous 2***

***median 1***

***role 4***

***Remarkably 2***

***squamous 1***

***fibrillization 2***

***Mdv1 1***

***understand 2***

***their 6***

***Modelled 1***

***rare 3***

***intraocular 2***

***useful 1***

***valuable 1***

***β-oxidation 1***

***Phenotype-Gene 1***

***monolayer 4***

***important 2***

***misunderstood 1***

***EphB3 10***

***possess 2***

***fitted 1***

***racial/ethnic 2***

***C-terminal 1***

***antigen 1***

***plasmid 4***

***MG 8***

***clearly 1***

***genotyping 1***

***brucei 1***

***Melatonin 1***

***nomenclature 1***

***leukemia 2***

***DNA 6***

***Atlas 1***

***switched 1***

***pre-cancerous 1***

***it 6***

***bacterial 1***

***tetrapeptide 2***

***boost 4***

***previous 1***

***secure 1***

***corresponding 4***

***oncogenes 2***

***To 5***

***clinics 1***

***caused 4***

***lysosomal 9***

***these 6***

***reserved.***

***1***

***explore 2***

***silenced 1***

***evolved 1***

***phenotypes 2***

***techniques 1***

***alone 1***

***adipose 1***

***reprogrammed 3***

***most 6***

***site 1***

***be 8***

***epigenetically 1***

***toward 1***

***packaging 4***

***U2AF1 3***

***levels 5***

***environment 6***

***cervical 5***

***pineal 1***

***official 1***

***dramatically 1***

***rRNA 1***

***beta-2-glycoprotein 2***

***stabilization 2***

***mitochondrial 1***

***scientists 1***

***off-target 4***

***siRNA 8***

***small 5***

***Lymphoma 2***

***suitable 1***

***treatments 1***

***tailoring 2***

***at 6***

***development 10***

***crossed 2***

***lymphoma 4***

***children 1***

***bovinised 1***

***sleep 2***

***Persistent 1***

***N-TAAP 2***

***laboratory 1***

***authoritative 1***

***milk 1***

***Nomenclature 1***

***forms 3***

***suggested 1***

***Barrier 2***

***or 11***

***improves 4***

***Tg1896 1***

***sequenced 1***

***termed 2***

***cytosol 4***

***effective 3***

***Illumina 1***

***amplified 1***

***functioned 1***

***kidneys 2***

***of 228***

***diagnostic 1***

***induces 4***

***management 4***

***receptors 1***

***investigate 2***

***Tuberous 2***

***therapies 4***

***WB 1***

***functions 1***

***reference 1***

***subjects 1***

***system 9***

***promotes 4***

***included.***

***2***

***misfolded 1***

***studies 1***

***diurnal 1***

***nucleus 3***

***PK 1***

***transmitted 1***

***researchers 1***

***GC.***

***1***

***ongoing 1***

***clinical 17***

***describe 5***

***absolute 1***

***metastatic 1***

***food-entrained 1***

***observations 1***

***cooperation 2***

***blot 1***

***remains 5***

***cortical 2***

***condition 2***

***frequently 1***

***vascular 2***

***did 1***

***TSC.***

***2***

***barrier 4***

***toxicity 12***

***terms 2***

***present 2***

***antimiRs 4***

***1998 2***

***65 1***

***diseases 9***

***diabetes 2***

***clonal 1***

***lines 9***

***pathophysiology 2***

***algorithm 1***

***0.78 3***

***L-BSE 2***

***cancers 1***

***do 1***

***carrying 4***

***hit 1***

***entity 2***

***gain 1***

***spliceosome 1***

***∼35% 1***

***phenotypic 1***

***graphical 1***

***far 2***

***user 1***

***structure 1***

***presence 1***

***pyridazine 1***

***recent 3***

***firewood 1***

***quality 3***

***confirmed 2***

***genome 2***

***risk 2***

***Tg 4***

***infection 5***

***related 5***

***cloned 1***

***adopted 2***

***known 2***

***fungal 2***

***higher 2***

***protein 5***

***GXD 1***

***KLF4 3***

***stable 3***

***species.***

***1***

***3 2***

***causal 1***

***reductive 4***

***rhodesiense 1***

***identified 2***

***infiltrative 4***

***aspects 2***

***pluripotency-associated 3***

***recessive 3***

***relationships 1***

***Development 2***

***decisions 2***

***involved 3***

***perspectives 2***

***that 34***

***context 1***

***many 10***

***triggers 1***

***strong 4***

***H-type 1***

***future 3***

***Database 2***

***age 1***

***availability 2***

***SMA 4***

***changes 1***

***enrichment 1***

***hematopoietic 2***

***suppressors 2***

***FANTOM 1***

***dodecapeptide 2***

***computation 1***

***pathological 2***

***Genome 3***

***such 13***

***routines 1***

***independently 1***

***loss 2***

***common 4***

***chemotherapy 4***

***storage 6***

***plaques 1***

***hand 2***

***bendamustine 2***

***required 7***

***spread 1***

***ILBF 1***

***dead.***

***1***

***includes 2***

***chimaeric 4***

***incorporation 1***

***not 7***

***U-87 8***

***reviews 2***

***Pro358Leu 3***

***downregulated 1***

***TMZ-based 2***

***provided 1***

***tyrosine 2***

***quantification 1***

***generated 6***

***HS 6***

***myeloid 2***

***periodicity 1***

***aglycosyl 1***

***naïve 1***

***rights 1***

***AD 6***

***EZH2 1***

***black 2***

***Bendamustine-rituximab 2***

***phase 2***

***L-type 1***

***itself 1***

***SF3B1 3***

***tumor 6***

***N-terminal 4***

***had 1***

***Valley 1***

***significance 2***

***on 13***

***et 3***

***across 1***

***pediatric 6***

***Management 2***

***transducer 1***

***factor 2***

***encephalopathy 2***

***Preclinically 2***

***durable 2***

***cases 5***

***enhancements 1***

***On 2***

***patterns 2***

***use 2***

***light-entrained 1***

***peptide-decorated 4***

***circulation 4***

***disorders 4***

***serve 1***

***contains 1***

***mode 2***

***primarily 1***

***Mitochondrial 1***

***compared 6***

***household 1***

***modifications 3***

***triggered 1***

***mediated 3***

***accepted 2***

***successfully 2***

***exclusively 1***

***paraventricular 1***

***These 2***

***sheep 3***

***zeitgeber 1***

***water 1***

***atypical 3***

***determination 1***

***revision 2***

***reticular 1***

***GVHD 2***

***immune 6***

***also 3***

***neuron 1***

***Cervical 1***

***wider 1***

***MCSP 2***

***significant 9***

***promotion 1***

***http//www.informatics.jax.org 1***

***latest 1***

***susceptibility 1***

***Lemonnier 3***

***reported 5***

***al. 3***

***hosts 1***

***evaluated 2***

***Luangwa 1***

***progression 6***

***rates 4***

***HR-HPV 2***

***threshold 1***

***source 1***

***bovine 3***

***attribution 1***

***cross-sectional 1***

***strategy 6***

***by 39***

***guidelines 1***

***like 2***

***peptidomimetic 2***

***It 5***

***conformation 1***

***regions 2***

***continuous 1***

***epigenetic 10***

***7 2***

***agent-based 1***

***mammalian 2***

***vector 5***

***growth 6***

***tandem 2***

***continue 1***

***Site 1***

***persistent 1***

***expressed 1***

***growing 1***

***evident 2***

***K 1***

***LIN28 3***

***initiative.***

***1***

***neuromuscular 1***

***based 3***

***inflammation 1***

***way 2***

***sclerosis 2***

***cattle 8***

***CIN3 1***

***approved 2***

***/ 1***

***key 2***

***nature 1***

***various 1***

***extension 2***

***observational 1***

***to 86***

***Sanfilippo 6***

***group 3***

***activity 6***

***where 1***

***quantitative 2***

***normal 3***

***kinase 2***

***dermal 3***

***and 222***

***mitigation 1***

***Blood-Brain 2***

***Reasons 1***

***synchronizes 1***

***being 2***

***copyright 1***

***well-targeted 1***

***Total WordNet Words: 1321***

***Words Count***

***included 2***

***under 1***

***immunohistochemistry 1***

***offer 1***

***interpretation 1***

***its 0***

***CXCR4 0***

***have 6***

***intake 8***

***highest 0***

***0015 0***

***several 1***

***Maximum 0***

***affected 1***

***been 0***

***obtained 0***

***multimodal 0***

***improved 4***

***appropriateness 1***

***meta-analysis 0***

***marked 1***

***100% 0***

***any 4***

***dermatitis 1***

***largely 1***

***over 1***

***met 0***

***breast/axillary 0***

***Our 0***

***amount 2***

***tool 1***

***dual 1***

***0004 0***

***are 12***

***reserved 1***

***p 7***

***conventional 1***

***attempted 1***

***address 1***

***history 8***

***our 0***

***prospective 1***

***magnetic 1***

***inclusion 1***

***multiple 2***

***biocompatibility 0***

***vivo 0***

***56% 0***

***better 1***

***prolonged 1***

***intra-operative 0***

***iron 1***

***inverse 1***

***them 0***

***utility 1***

***recently 1***

***IMAGING 0***

***imaging 22***

***showed 0***

***receiving 0***

***comprehensive 1***

***Conventional 0***

***long 2***

***375% 0***

***evaluation 1***

***images 0***

***overcome 1***

***traumatic 3***

***total 2***

***using 4***

***moist 1***

***estimated 0***

***Ag2S-NP 0***

***they 0***

***new 2***

***tumour 3***

***defines 0***

***CONCLUSIONS 0***

***Despite 0***

***separately 1***

***characteristics 0***

***treatment 5***

***discovery 1***

***due 3***

***suggest 3***

***ion 1***

***concept 1***

***after 7***

***8 1***

***Tumour 0***

***ILC 0***

***70% 0***

***family 8***

***completion 2***

***hormonal 2***

***coupled 1***

***low 1***

***cornerstone 1***

***energy 1***

***dietary 3***

***bleeding 1***

***Cancer 0***

***MRI 0***

***technique 1***

***Female 0***

***outperforms 0***

***95 1***

***proliferation 1***

***mass 1***

***OS 0***

***observed 3***

***assess 1***

***resolution 1***

***protocol 1***

***term 1***

***19 1***

***There 0***

***therefore 1***

***general 1***

***earlier 1***

***P 0***

***locally 1***

***developed 2***

***some 1***

***only 3***

***complex 1***

***first 1***

***31122014 0***

***without 0***

***already 1***

***what 0***

***too 1***

***adenomas 0***

***lymph 3***

***analysis 4***

***performance 1***

***negligible 1***

***developments 0***

***rule 1***

***cancer 47***

***expenditures 0***

***diet 2***

***few 1***

***typical 1***

***MATERIALS 0***

***can 2***

***signature 2***

***ratios 0***

***clustering 1***

***LEVEL 0***

***search 1***

***SUVmax 0***

***there 3***

***none 1***

***recorded 1***

***into 0***

***digital 1***

***kg/m2 0***

***Traumatic 0***

***258% 0***

***feasible; 0***

***probe 2***

***initial 1***

***variable 1***

***Further 0***

***Therefore 0***

***< 0***

***analyzed 1***

***continuing 1***

***micelles 0***

***radiology 1***

***088-099; 0***

***play 1***

***4 1***

***review 4***

***receptor 6***

***NAC 0***

***They 0***

***older 1***

***later 2***

***targeted 0***

***life 2***

***significantly 9***

***molecular 3***

***Ulceration 0***

***emerging 1***

***neuromas 0***

***expression 2***

***derivatives 0***

***cytotoxicity 1***

***identify 1***

***surgical 3***

***promote 1***

***disease 7***

***IORT 0***

***duration 2***

***contribution 1***

***understanding 1***

***g/day 0***

***relative 1***

***Efficacy 0***

***other 2***

***further 2***

***removed 1***

***among 0***

***two 1***

***high-dose 0***

***curbing 1***

***prolactinomas 0***

***indicative 1***

***clinic 1***

***allowed 0***

***fast 2***

***performed 0***

***between 10***

***demonstrated 2***

***novel 1***

***report 2***

***checkpoint 1***

***0***

***factors 0***

***yielded 0***

***tomography 1***

***lead 1***

***aforementioned 1***

***accurate 1***

***users 0***

***so 1***

***case 2***

***revealed 0***

***commonly 1***

***hormone 1***

***DEM 0***

***underwent 0***

***replaced 0***

***young 1***

***0001 0***

***301% 0***

***unresectable 0***

***shorten 1***

***surgery 10***

***The 0***

***I2 0***

***For 0***

***than 0***

***minimal 1***

***Patient 0***

***routinely 1***

***analyzing 0***

***having 0***

***received 2***

***Moreover 0***

***result 2***

***EMBASE 0***

***lesions 0***

***84% 0***

***herein 2***

***visually 3***

***used 3***

***shown 0***

***103% 0***

***modality 2***

***study 7***

***along 1***

***epidermal 1***

***less 1***

***determined 2***

***relatively 1***

***human 1***

***the 0***

***aim 2***

***intrinsic 1***

***cohort 5***

***production 7***

***applied 1***

***different 2***

***invasive 3***

***longer 1***

***PET/CT 0***

***given 1***

***population 2***

***all 4***

***accuracy 2***

***including 0***

***computed 0***

***necessity 1***

***generally 1***

***asymptomatic 1***

***but 3***

***tracer 1***

***patient's 0***

***patient 5***

***treated 1***

***clear 1***

***per 0***

***pill 1***

***collected 1***

***shared 1***

***Overall 0***

***about 1***

***carcinogenesis 0***

***possible 1***

***distant 2***

***while 2***

***features 0***

***standardized 2***

***intractable 1***

***radiation 2***

***DiR 0***

***002; 0***

***30 1***

***abbreviated 5***

***examination 1***

***overview 1***

***special 1***

***recovery 1***

***1 3***

***nanoparticles 0***

***give 1***

***may 6***

***properly 1***

***supplement 1***

***find 2***

***050-099; 0***

***scan 1***

***main 1***

***Breast 0***

***breast 53***

***investigated 0***

***available 2***

***subtypes 0***

***alternative 1***

***fluorophore 0***

***more 3***

***investigations 0***

***121% 0***

***NFPA 0***

***An 0***

***does 0***

***introduced 0***

***occurred 0***

***contrast-enhanced 0***

***12 1***

***44% 0***

***trials 0***

***palliative 1***

***modified 1***

***formation 1***

***seems 0***

***percent 1***

***agent 3***

***positive 2***

***particular 2***

***limitations 0***

***retrospective 3***

***second- 0***

***PA 0***

***symptom 1***

***CT 0***

***DCE-MRI 0***

***outcomes 0***

***each 2***

***A 0***

***40% 0***

***inception 1***

***Comparison 0***

***1200 0***

***non-ideal 0***

***following 2***

***estrogen 2***

***association 5***

***range 2***

***which 0***

***healthcare 3***

***wane 1***

***predict 1***

***require 1***

***needed 1***

***for 0***

***biology 1***

***cost 1***

***whether 0***

***obtain 1***

***Danish 0***

***behaviors 0***

***control 1***

***time 3***

***CXCR4-targeted 0***

***placed 1***

***HER2 0***

***summarize 1***

***much 1***

***heterogeneous 1***

***oxide 1***

***four-month 0***

***literature 2***

***Forty-two 0***

***evidenced 1***

***indicate 1***

***apparent 1***

***5 1***

***was 0***

***P=04 0***

***nodes 0***

***subtype-specific 0***

***systemic 3***

***no 3***

***detectable 2***

***ER 0***

***95% 0***

***chest 1***

***Ten 0***

***younger 1***

***mean 2***

***If 0***

***an 10***

***both 2***

***current 3***

***value 2***

***vs 0***

***2018 0***

***model 2***

***members 0***

***Technical 0***

***Both 0***

***159 0***

***Healthcare 0***

***contraception 2***

***phantom 1***

***070 0***

***major 1***

***X-ray 0***

***number 1***

***interval 2***

***consider 1***

***therapy 3***

***0049 0***

***in 62***

***provide 1***

***described 1***

***develop 2***

***accumulation 1***

***lycopene 1***

***simplify 1***

***In 0***

***diagnosis 14***

***good 1***

***update 1***

***IO-NP 0***

***silver 2***

***detection 2***

***representative 1***

***Furthermore 0***

***view 1***

***trend 1***

***= 0***

***466% 0***

***progesterone 1***

***negative 2***

***reflect 1***

***genetic 1***

***a 49***

***ethinyl 0***

***exhibiting 0***

***adjustment 1***

***Given 0***

***effect 1***

***considering 0***

***CXCR4-directed 0***

***benign 2***

***acquisition 1***

***Notably 0***

***especially 1***

***Conservative 0***

***Meta-regression 0***

***were 0***

***Herein 0***

***overall 3***

***designed 1***

***lower 1***

***response 1***

***tissue 1***

***pathways 0***

***index 3***

***pain 2***

***approaches 0***

***excision 1***

***BACKGROUND 0***

***intervals 0***

***neuropathic 0***

***b-carotene 0***

***presentation 3***

***lung 4***

***policy 1***

***013 0***

***type 3***

***screening 3***

***we 0***

***This 0***

***measured 2***

***who 1***

***third-degree 0***

***28 1***

***however 1***

***Metastases 0***

***contrast 9***

***124% 0***

***13 2***

***153% 0***

***years 7***

***Nine 0***

***61% 0***

***out 1***

***presented 0***

***triple 1***

***093 0***

***cohort; 0***

***2005-2017 0***

***article 1***

***focusing 1***

***fee-for-service 0***

***completing 1***

***findings 2***

***sulfide 1***

***hazard 2***

***when 0***

***recurrent 4***

***aims 0***

***sought 1***

***eg 0***

***as 10***

***medicine 1***

***"all-in-one" 0***

***signaling 1***

***31 1***

***values 1***

***survival 8***

***symptoms 0***

***excluded 0***

***thus 1***

***progression-free 0***

***status 1***

***independent 2***

***prediagnosis 0***

***originally 2***

***issues 0***

***versus 0***

***Locoregional 0***

***is 0***

***found 2***

***chart 1***

***associated 0***

***extent 2***

***ability 1***

***methods 0***

***unresected 0***

***0-30125 0***

***We 0***

***rising 1***

***profiles 0***

***54% 0***

***primary 7***

***Median 0***

***mechanisms 0***

***Although 0***

***now 2***

***has 0***

***four 1***

***DWI 0***

***axillary 1***

***University 0***

***Colorectal 0***

***safety 1***

***set 1***

***Stage 0***

***body 1***

***via 0***

***acromegaly 1***

***RESULTS 0***

***effects 3***

***prior 1***

***tumour-related 0***

***discomfort 1***

***b-cryptoxanthin 0***

***35 2***

***Hospital 0***

***LABC 0***

***As 0***

***families 0***

***8/18 0***

***requires 0***

***indicates 0***

***20-mcg 0***

***examinations 0***

***diagnosed 0***

***nanoparticle 0***

***framework 1***

***locoregional 0***

***often 1***

***five 1***

***lesion 2***

***breast-conserving 0***

***mainly 1***

***this 0***

***BMI 0***

***experienced 1***

***cell 1***

***results 0***

***patients 0***

***member 1***

***agreement 1***

***METHODS 0***

***J 0***

***tumor-to-background 0***

***fluorescence 1***

***24 2***

***unknown 2***

***Lung 0***

***correlation 2***

***demographics 0***

***conserving 0***

***node 1***

***Ulm 0***

***mastectomy 3***

***test 1***

***timing 1***

***non-functioning 0***

***60 2***

***limited 1***

***advanced 2***

***disproportionate 1***

***potent 1***

***58% 0***

***When 0***

***Patients 0***

***prognostic 10***

***outcome 1***

***seem 1***

***581 0***

***resonance 1***

***reproducibility 1***

***subtype 0***

***potential 1***

***numerous 1***

***study; 0***

***involves 0***

***agents 0***

***However 0***

***implemented 1***

***computational 1***

***collect 1***

***high 4***

***assessing 0***

***experience 1***

***currently 2***

***PR 0***

***uptake 1***

***therapeutic 1***

***metastasis 2***

***mammography 3***

***one 3***

***with 0***

***2 2***

***January 0***

***data 1***

***gene-expression-based 0***

***increased 5***

***specific 2***

***2004 0***

***shrinkage 2***

***women 0***

***explained 0***

***breasts 0***

***increase 1***

***investigation 1***

***populations 0***

***from 0***

***109 0***

***proportion 1***

***460 0***

***options 0***

***Radiotherapy 0***

***median 1***

***role 3***

***stage 1***

***date 1***

***near-infrared 0***

***radiotherapy 11***

***summary 2***

***because 0***

***consistent 1***

***their 0***

***sensitive 1***

***lowest 1***

***rare 3***

***useful 1***

***Twenty-six 0***

***get 1***

***widespread 1***

***trial 1***

***intrauterine 1***

***radical 1***

***confidence 3***

***very 6***

***stratification 1***

***advance 1***

***important 3***

***vitamin 4***

***precision 1***

***wall 1***

***identification 1***

***prognosis 2***

***metastases 0***

***length 1***

***undetectable 1***

***costs 2***

***ER+ 0***

***co-encapsulation 0***

***dynamic 1***

***value-based 0***

***neuroma 3***

***it 3***

***neoadjuvant 0***

***previous 3***

***pathological 1***

***delay 1***

***such 4***

***formed 1***

***discussed 0***

***intervention 1***

***missed 1***

***436 0***

***levonorgestrel 0***

***a-carotene 0***

***evidence 1***

***chemotherapy 1***

***corresponding 1***

***suspicion 1***

***7/18 0***

***applications 0***

***CONCLUSION 0***

***Diagnostic 0***

***25 5***

***To 0***

***Future 0***

***19450 0***

***1062 0***

***required 1***

***substantially 1***

***these 0***

***research 1***

***paradigm 1***

***inconsistent 1***

***release 1***

***conducted 0***

***Thirteen 0***

***techniques 0***

***not 10***

***process 1***

***enable 1***

***carcinoma 2***

***most 4***

***practice 1***

***detectability 0***

***provided 0***

***68Ga-Pentixafor 0***

***be 8***

***modalities 0***

***256 0***

***axilla 1***

***2016 0***

***generated 0***

***larger 1***

***EVIDENCE 0***

***scrutiny 1***

***AND 0***

***ml 2***

***tomosynthesis 0***

***functional 1***

***PEGylated 0***

***increasing 2***

***tumor 4***

***ratio 1***

***follow-up 1***

***malignancy 2***

***Based 0***

***small 4***

***concerns 0***

***necessary 2***

***36 1***

***had 0***

***on 11***

***suitable 1***

***signatures 0***

***Management 0***

***summarized 0***

***before 5***

***pooled 0***

***at 9***

***01012010 0***

***diffusion-weighted 0***

***random 1***

***175 1***

***164 0***

***and/or 0***

***T/B 0***

***factor 3***

***outpatient 1***

***overexpressed 0***

***gadolinium-based 0***

***RESON 0***

***sampling 1***

***reviewed 0***

***relatives 0***

***cases 0***

***drains 0***

***use 5***

***multi-omics 0***

***image 1***

***pituitary 2***

***reduction 1***

***or 9***

***compared 0***

***wound 1***

***effective 2***

***properties 0***

***of 0***

***diagnostic 5***

***tools 0***

***months 0***

***management 2***

***lutein 1***

***possibility 1***

***desquamation 1***

***investigate 1***

***assessed 0***

***potentially 1***

***therapies 0***

***inhibitory 1***

***seroma 0***

***variation 2***

***retinol 1***

***These 0***

***Forty-three 0***

***studies 0***

***existing 1***

***definitive 1***

***825 0***

***MAGN 0***

***maintaining 0***

***People 0***

***makers 0***

***clinical 4***

***PET 0***

***Efforts 0***

***metastatic 3***

***selected 1***

***immune 2***

***grade 2***

***side 1***

***colon 2***

***remains 2***

***injection 1***

***regional 1***

***should 0***

***frequently 1***

***significant 3***

***did 0***

***Centre 0***

***cancer-specific 0***

***prediction 2***

***estradiol 1***

***present 3***

***latest 1***

***susceptibility 1***

***reported 8***

***also 1***

***NST 0***

***locally-advanced 0***

***limit 1***

***NIRF 0***

***cancers 0***

***exam 1***

***72 1***

***387% 0***

***feasible 2***

***entity 1***

***by 4***

***far 1***

***presence 1***

***recent 3***

***presenting 0***

***criteria 0***

***quality 1***

***confirmed 1***

***risk 11***

***0033; 0***

***beam 1***

***14 1***

***68% 0***

***increment 1***

***60% 0***

***growth 1***

***whole 1***

***PubMed 0***

***might 1***

***higher 7***

***semi-quantitatively 0***

***external 1***

***chemokine 0***

***3 1***

***dense 1***

***consistently 1***

***based 1***

***18F-FDG 0***

***prolactinoma 0***

***refractory 1***

***stratified 1***

***OF 0***

***within 1***

***P=02 0***

***Hence 0***

***involved 1***

***appealing 1***

***underlines 0***

***that 0***

***protocols 0***

***many 1***

***lobular 1***

***Multivariate 0***

***sensitivity 1***

***AION 0***

***strong 4***

***large 1***

***to 0***

***system-both 0***

***applicable 1***

***broader 0***

***20% 0***

***differential 1***

***age 5***

***Seroma 0***

***ultrasound 1***

***unenhanced 0***

***and 0***

***being 2***

***familial 1***

***postmenopausal 1***

1. ***Create a single Ontology from the approximate 50 abstracts***
   1. ***Report the entities***

***Species***

***Disease***

***Chemical***

***Gene***

* 1. ***Report the predicates***

***meanSUVmaxOf***

***isClinicalEntityWith***

***wereDiagnosedAt***

***has***

***isRareClinicalEntityWith***

***suggest***

***wereIncludedIn***

***accumulatedAfter***

***areRareBenignLesions***

***isMostEffectiveAndEfficientTechniqueusedFor***

***isEmergingAs***

***isCurrentlyOnlyRoutinelyImplementedAt***

***isMostCommonCancerAmong***

***generating***

***HenceIsCurrentlyImplementedAt***

***mayEnable***

***requires***

***indicates***

***discussedManagementWith***

***hasLedTo***

***wasGreaterAt***

***areInvolvedIn***

***UnfortunatelyRelapsedWith***

***outperformsImagingWith***

***areNecessaryIn***

***outperforms***

***receivedTreatmentFor***

***assess***

***isVeryRareClinicalEntityWith***

***amountOfWas***

***wereDevelopedIn***

***developed***

***systematicallyAnalyzedGlycosylationBy***

***areStillNecessaryIn***

***isCurrentlyRoutinelyImplementedAt***

***isMostInvasiveDiseaseNextTo***

***OverallHad***

***evidenceFor***

***numberOf***

***areUsedIn***

***HenceIsImplementedAt***

***exploitPARPTreatmentsIn***

***wereVisuallyDetectableIn***

***isOnlyRoutinelyImplementedAt***

***calculate***

***lackOf***

***isIndependentFactorIn***

***summarizedSignaturesWith***

***relapsedLaterWith***

***isFactorIn***

***isVeryComplexAndHeterogeneousDiseaseWith***

***limitedEvidenceFor***

***areConcernsInSpiteOf***

***HereAnalyzed***

***exploreStrategiesByMeansOf***

***incorporate***

***isMostEffectiveTechniqueusedFor***

***regulating***

***isIndicatorOf***

***isDiseaseWith***

***analyzed***

***ThereforeSystematicallyAnalyzedGlycosylationBy***

***collect***

***ThereforeAnalyzedGlycosylationBy***

***remainsFollowing***

***ruleOut***

***areMoreCommonlyDiagnosedBefore***

***areVeryRareBenignLesions***

***presentCaseIn***

***assessing***

***haveSensitivityIn***

***determinedBy***

***ThereforeAnalyzed***

***conjugated***

***HenceIsCurrentlyImplementedIn***

***isVeryComplexDiseaseWith***

***444Women***

***confirmedFor***

***explained***

***analyzedGlycosylationBy***

***ThereforeSystematicallyAnalyzed***

***identify***

***HenceIsImplementedIn***

***describedIn***

***hasLedIn***

***isOnlyRoutinelyImplementedIn***

***relapsedWith***

***isCurrentlyRoutinelyImplementedIn***

***isCancerAmong***

***curbing***

***isTechniqueusedFor***

***Using***

***allowed***

***isRoutinelyImplementedIn***

***classifyImagesInto***

***demonstrated***

***isComplexAndHeterogeneousDiseaseWith***

***yielded***

***isCommonCancerIn***

***MedianAmountOfWas***

***considerIn***

***metInclusionCriteriaIn***

***TraumaticNeuromaOfIs***

***isShapedBy***

***wereStratifiedBasedOn***

***systematicallyAnalyzed***

***beInvolvedIn***

***wasExpressedIn***

***discoveredAccordingTo***

***areDiagnosedBefore***

***exploitPlatinumSaltsIn***

***isRequired***

***wasHigherThan***

***willAidIn***

***remainsDespite***

***alsoImprove***

***received***

***discussed***

***ThereforeInvestigated***

***wasSignificantlyHigherThan***

***wereFormedBy***

***calculateConfidenceIntervalsFor***

***usingMSOTWith***

***definedAspirinUseIn***

***target***

***explore***

***goodResponseIn***

***isStrongIndependentPrognosticFactorIn***

***applied***

***areVeryRareLesions***

***enable***

***wasUnusualFor***

***patientWith***

***diagnosedIn***

***wasDifferentiallyExpressedIn***

***provided***

***be***

***allowedTumorImaging***

***generated***

***wasEstablishedBasedOn***

***isCurrentlyImplementedAt***

***Performing***

***of13Is***

***presentingWith***

***HenceIsCurrentlyOnlyRoutinelyImplementedIn***

***000Deaths***

***isStrongAndSignificantPrognosticFactorIn***

***wasReportedIn***

***isAppliedAfter***

***isVeryRareEntityWith***

***areLesions***

***curbingUse***

***isStrongAndSignificantIndependentFactorIn***

***wouldFacilitate***

***treated***

***exploit***

***wasRecentlyFound***

***areStillNecessaryAs***

***wereNewlyIdentifiedAmong***

***distinguish***

***summarized***

***had***

***would***

***wereIdentifiedIn***

***HenceIsOnlyRoutinelyImplementedAt***

***isStrongFactorIn***

***HenceIsOnlyRoutinelyImplementedIn***

***wasFactorFor***

***OverallAreImportantFactors***

***HenceIsCurrentlyOnlyRoutinelyImplementedAt***

***issuesOf***

***HenceIsRoutinelyImplementedIn***

***areNecessaryAs***

***reviewed***

***withCasesIs***

***isInvasiveDiseaseNextTo***

***isSignificantlyLowerComparedTo***

***give***

***isCancerIn***

***may***

***howeverHasRemained***

***HenceIsRoutinelyImplementedAt***

***waneWith***

***wasGreaterRespectivelyThan***

***FurthermoreWereDiagnosedAt***

***areAt***

***isImplementedIn***

***isStrongAndSignificantIndependentPrognosticFactorIn***

***investigated***

***isStrongPrognosticFactorIn***

***wasGreaterRespectivelyIn***

***generate***

***isImplementedAt***

***FinallyIsEmergingAs***

***assessed***

***isEffectiveAndEfficientTechniqueusedFor***

***improvedFollowing***

***examined***

***seems***

***isRareEntityWith***

***improvedIn***

***areMajorConcernsInSpiteOf***

***isStrongIndependentFactorIn***

***isEntityWith***

***considerNeuromaIn***

***wereDiagnosedWith***

***wasFound***

***hereinPresentCaseIn***

***isAccomplishedBy***

***frequentlyOverexpressedIn***

***wereDetectableIn***

***HenceSought***

***MoreImportantlyHad***

***predict***

***isAlsoShapedBy***

***remains***

***onlyReceived***

***definesValueAs***

***obtain***

***usedConcurrentlyWith***

***present***

***hasRemained***

***compare***

***reported***

***isFeasibleAfter***

***collectFamilyHistoryIn***

***isProtectedBy***

***HenceIsCurrentlyRoutinelyImplementedAt***

***wasGreaterRespectivelyAt***

***wereFormedIn***

***wasConfirmedIn***

***was***

***limit***

***metIn***

***areCommonlyDiagnosedBefore***

***isAdditionalIndicatorOf***

***isStrongAndSignificantFactorIn***

***isPromisingFor***

***usedWith***

***defined***

***isEffectiveTechniqueusedFor***

***demonstratedIn***

***isIn***

***isCommonCancerAmong***

***howeverIsLowerComparedTo***

***confirmed***

***wasPerformedFrom***

***howeverIsSignificantlyLowerComparedTo***

***consider***

***HerePresent***

***summarizedWith***

***isMostCommonCancerIn***

***provide***

***develop***

***isTestFor***

***isCurrentlyImplementedIn***

***simplify***

***MRIOfIs***

***developedCBCDuring***

***calculateHazardRatiosFor***

***isIn***

***haveProvided***

***MoreoverInduced***

***=***

***wereAvailableIn***

***areRareLesions***

***isNecessary***

***OverallAreFactors***

***separatelyAssessed***

***isReservedFor***

***SUVmaxOf***

***isSensitiveTestFor***

***exploreStrategiesThrough***

***underlines***

* 1. ***Report the triplets***

***study,collectFamilyHistoryIn,cohortOfPatientsWithAdenomasInOutpatientClinic,Obj***

***study,collectFamilyHistoryIn,cohortOfPatients,Obj***

***patients,isIn,outpatientClinic,Obj***

***study,collect,familyHistory,Obj***

***study,collect,familyHistoryOfCancer,Obj***

***study,collectFamilyHistoryIn,largeCohortOfPatientsWithPituitaryAdenomas,Obj***

***study,collectFamilyHistoryIn,largeCohortOfPatientsWithAdenomasInOutpatientClinic,Obj***

***study,collectFamilyHistoryIn,largeCohortOfPatients,Obj***

***study,collectFamilyHistoryIn,cohortOfPatientsWithPituitaryAdenomas,Obj***

***study,collectFamilyHistoryIn,largeCohortOfPatientsInOutpatientClinic,Obj***

***patients,isWith,pituitaryAdenomas,Obj***

***study,collectFamilyHistoryIn,cohortOfPatientsWithAdenomas,Obj***

***%,overallHad,familyMemberAffected,Obj***

***1062Patients,isWith,PA,Obj***

***466%,had,familyMemberAffected,Obj***

***466%,had,familyMember,Obj***

***466%,overallHad,familyMemberAffectedWithCancer,Obj***

***%,overallHad,familyMemberAffectedWithCancer,Obj***

***466%,overallHad,familyMemberAffected,Obj***

***%,had,familyMemberAffected,Obj***

***%,had,familyMemberAffectedWithCancer,Obj***

***466%,overallHad,familyMember,Obj***

***%,overallHad,familyMember,Obj***

***%,had,familyMember,Obj***

***466%,had,familyMemberAffectedWithCancer,Obj***

***breastCancer,isIn,familyMembers,Obj***

***acromegaly,wasSignificantlyHigherThan,thanFamilies,Obj***

***acromegaly,wasSignificantlyHigherThan,thanFamiliesOfPatientsWithNon-functioningPituitaryAdenomas,Obj***

***acromegaly,was,higher,Obj***

***acromegaly,wasSignificantlyHigherThan,thanFamiliesOfPatientsWithAdenomas,Obj***

***acromegaly,wasSignificantlyHigherThan,thanFamiliesOfPatientsWithNon-functioningAdenomas,Obj***

***acromegaly,wasHigherThan,thanFamiliesOfPatients,Obj***

***patients,isWith,non-functioningPituitaryAdenomas,Obj***

***acromegaly,wasHigherThan,thanFamiliesOfPatientsWithNon-functioningAdenomas,Obj***

***breastCancer,was,reported,Obj***

***acromegaly,wasHigherThan,thanFamiliesOfPatientsWithPituitaryAdenomas,Obj***

***acromegaly,wasHigherThan,thanFamilies,Obj***

***patients,isWith,prolactinomas,Obj***

***acromegaly,wasSignificantlyHigherThan,thanFamiliesOfPatients,Obj***

***p,=,0.004,Obj***

***acromegaly,was,significantlyHigher,Obj***

***acromegaly,wasHigherThan,thanFamiliesOfPatientsWithAdenomas,Obj***

***acromegaly,wasSignificantlyHigherThan,thanFamiliesOfPatientsWithPituitaryAdenomas,Obj***

***acromegaly,wasHigherThan,thanFamiliesOfPatientsWithNon-functioningPituitaryAdenomas,Obj***

***lungCancer,wasReported,significantlyHigher,Obj***

***lungCancer,wasReportedIn,121%OfPatientsWithProlactinomas,Obj***

***lungCancer,was,reported,Obj***

***lungCancer,isIn,familyMembers,Obj***

***lungCancer,wasReportedIn,121%,Obj***

***lungCancer,wasReportedIn,121%OfPatients,Obj***

***lungCancer,wasReported,higher,Obj***

***lungCancer,wasReported,higherThanInFamilies,Obj***

***lungCancer,wasReported,higherThanInFamiliesOfNfpaPatients,Obj***

***lungCancer,wasReported,significantlyHigherThanInFamilies,Obj***

***lungCancer,wasReported,significantlyHigherThanInFamiliesOfNfpaPatients,Obj***

***colorectalCancer,isIn,relativesOfPatientsWithPa,Obj***

***colorectalCancer,wasReportedWith,typeOfPa,Obj***

***cancer,wasReportedWith,typeOfPa,Obj***

***patients,isWith,PA,Obj***

***patients,furthermoreWereDiagnosedAt,earlierAgeThanPatientsWithFamilyHistory,Obj***

***patients,furthermoreWereDiagnosedAt,ageThanPatientsWithNegativeFamilyHistory,Obj***

***patients,furthermoreWereDiagnosedAt,earlierAgeThanPatientsWithNegativeFamilyHistory,Obj***

***patients,furthermoreWereDiagnosedAt,age,Obj***

***patients,were,furthermoreDiagnosedWithPaAtEarlierAgeThanPatientsWithFamilyHistory,Obj***

***patients,furthermoreWereDiagnosedAt,earlierAge,Obj***

***patients,furthermoreWereDiagnosedAt,ageThanPatientsWithFamilyHistory,Obj***

***patients,were,furthermoreDiagnosedWithPaAtAgeThanPatients,Obj***

***patients,were,furthermoreDiagnosedWithPaAtEarlierAge,Obj***

***patients,were,diagnosedWithPaAtEarlierAgeThanPatientsWithNegativeFamilyHistory,Obj***

***patients,were,furthermoreDiagnosedWithPaAtEarlierAgeThanPatientsWithNegativeFamilyHistory,Obj***

***patients,were,furthermoreDiagnosedWithPaAtAge,Obj***

***patients,furthermoreWereDiagnosedAt,ageThanPatients,Obj***

***patients,wereDiagnosedAt,earlierAgeThanPatientsWithNegativeFamilyHistory,Obj***

***patients,wereDiagnosedAt,age,Obj***

***patients,were,diagnosedWithPaAtAgeThanPatientsWithFamilyHistory,Obj***

***patients,were,diagnosedWithPaAtEarlierAgeThanPatientsWithFamilyHistory,Obj***

***patients,were,diagnosedWithPaAtAgeThanPatientsWithNegativeFamilyHistory,Obj***

***patients,wereDiagnosedAt,earlierAge,Obj***

***patients,furthermoreWereDiagnosedAt,earlierAgeThanPatients,Obj***

***patients,wereDiagnosedAt,ageThanPatients,Obj***

***patients,isWith,positiveFamilyHistoryOfMalignancy,Obj***

***patients,wereDiagnosedWith,PA,Obj***

***patients,wereDiagnosedAt,earlierAgeThanPatients,Obj***

***patients,isWith,negativeFamilyHistory,Obj***

***patients,were,diagnosedWithPaAtEarlierAge,Obj***

***patients,were,furthermoreDiagnosedWithPaAtEarlierAgeThanPatients,Obj***

***patients,were,diagnosedWithPaAtAgeThanPatients,Obj***

***patients,furthermoreWereDiagnosedWith,PA,Obj***

***patients,were,diagnosedWithPaAtEarlierAgeThanPatients,Obj***

***patients,were,diagnosed,Obj***

***patients,wereDiagnosedAt,ageThanPatientsWithNegativeFamilyHistory,Obj***

***patients,wereDiagnosedAt,ageThanPatientsWithFamilyHistory,Obj***

***patients,were,furthermoreDiagnosed,Obj***

***patients,were,furthermoreDiagnosedWithPaAtAgeThanPatientsWithFamilyHistory,Obj***

***patients,wereDiagnosedAt,earlierAgeThanPatientsWithFamilyHistory,Obj***

***patients,were,furthermoreDiagnosedWithPaAtAgeThanPatientsWithNegativeFamilyHistory,Obj***

***patients,were,diagnosedWithPaAtAge,Obj***

***patients,areCommonlyDiagnosedBefore,ageOf25Years,Obj***

***femalePatients,are,moreCommonlyDiagnosed,Obj***

***patients,are,diagnosed,Obj***

***patients,areDiagnosedBefore,age,Obj***

***femalePatients,isWith,prolactinoma,Obj***

***femalePatients,areMoreCommonlyDiagnosedBefore,age,Obj***

***patients,are,commonlyDiagnosed,Obj***

***femalePatients,are,commonlyDiagnosed,Obj***

***femalePatients,are,diagnosed,Obj***

***patients,areMoreCommonlyDiagnosedBefore,ageOf25Years,Obj***

***femalePatients,areMoreCommonlyDiagnosedBefore,ageOf25Years,Obj***

***patients,areMoreCommonlyDiagnosedBefore,age,Obj***

***patients,are,moreCommonlyDiagnosed,Obj***

***femalePatients,areDiagnosedBefore,ageOf25Years,Obj***

***patients,areCommonlyDiagnosedBefore,age,Obj***

***femalePatients,areCommonlyDiagnosedBefore,ageOf25Years,Obj***

***femalePatients,areCommonlyDiagnosedBefore,age,Obj***

***femalePatients,areDiagnosedBefore,age,Obj***

***patients,areDiagnosedBefore,ageOf25Years,Obj***

***higher,diagnosedLaterIn,life,Obj***

***higher,diagnosedIn,life,Obj***

***third-degree,were,reportedInProportionOfPatientsWithPa,Obj***

***patients,diagnosedIn,life,Obj***

***third-degree,were,reportedInHigherProportionOfPatients,Obj***

***Breast,isIn,second,Obj***

***third-degree,were,reportedInSignificantlyHigherProportionOfPatients,Obj***

***third-degree,were,reportedInSignificantlyHigherProportion,Obj***

***third-degree,were,reported,Obj***

***third-degree,were,reportedInProportion,Obj***

***patients,diagnosedLaterIn,life,Obj***

***third-degree,were,reportedInHigherProportionOfPatientsWithPa,Obj***

***third-degree,were,reportedInSignificantlyHigherProportionOfPatientsWithPa,Obj***

***third-degree,were,reportedInHigherProportion,Obj***

***third-degree,were,reportedInProportionOfPatients,Obj***

***results,suggest,cancerClusteringInPatientsWithProlactinoma,Obj***

***patients,isWith,prolactinoma,Obj***

***familialCancerClustering,isIn,patientsWithProlactinoma,Obj***

***results,suggest,familialCancerClustering,Obj***

***youngPatients,isWith,PA,Obj***

***results,suggest,familialCancerClusteringInPatients,Obj***

***results,suggest,cancerClusteringInPatients,Obj***

***results,suggest,familialCancerClusteringInPatientsWithProlactinoma,Obj***

***results,suggest,cancerClustering,Obj***

***strongAssociation,isIn,particular,Obj***

***association,isIn,particular,Obj***

***research,is,needed,Obj***

***furtherResearch,is,needed,Obj***

***BACKGROUND,determinedBy,multipleFactors,Obj***

***radiotherapy,may,mayUsed,Obj***

***radiotherapy,may,mayUsedForTumourShrinkage,Obj***

***radiotherapy,may,mayUsedForTumourShrinkagePrior,Obj***

***tumour,remainsFollowing,systemicTherapy,Obj***

***primaryTumour,remainsFollowing,therapy,Obj***

***radiotherapy,may,mayUsedForTumourShrinkagePriorToSurgery,Obj***

***tumour,remainsFollowing,therapy,Obj***

***primaryTumour,remains,unresectable,Obj***

***primaryTumour,remainsFollowing,systemicTherapy,Obj***

***tumour,remains,unresectable,Obj***

***disease,is,present,Obj***

***radiotherapy,is,reserved,Obj***

***metastaticDisease,is,whenPresent,Obj***

***radiotherapy,isGenerallyReservedFor,managementOfSymptoms,Obj***

***locoregionalRadiotherapy,is,generallyReserved,Obj***

***radiotherapy,isReservedFor,managementOfTumour-relatedSymptoms,Obj***

***radiotherapy,isReservedFor,management,Obj***

***locoregionalRadiotherapy,isReservedFor,managementOfTumour-relatedSymptoms,Obj***

***locoregionalRadiotherapy,is,reserved,Obj***

***radiotherapy,isGenerallyReservedFor,management,Obj***

***radiotherapy,is,generallyReserved,Obj***

***radiotherapy,isReservedFor,managementOfSymptoms,Obj***

***locoregionalRadiotherapy,isReservedFor,management,Obj***

***disease,is,whenPresent,Obj***

***locoregionalRadiotherapy,isReservedFor,managementOfSymptoms,Obj***

***locoregionalRadiotherapy,isGenerallyReservedFor,managementOfSymptoms,Obj***

***metastaticDisease,is,present,Obj***

***locoregionalRadiotherapy,isGenerallyReservedFor,managementOfTumour-relatedSymptoms,Obj***

***locoregionalRadiotherapy,isGenerallyReservedFor,management,Obj***

***radiotherapy,isGenerallyReservedFor,managementOfTumour-relatedSymptoms,Obj***

***We,reviewed,ourExperience,Obj***

***We,reviewed,ourExperienceOfHigh-doseRadiotherapy,Obj***

***We,reviewed,ourExperienceOfRadiotherapy,Obj***

***patients,isWith,unresectedLocallyAdvancedBreastCancer,Obj***

***Patients,wereStratifiedBasedOn,presenceOfMetastaticDisease,Obj***

***Patients,wereStratifiedBasedOn,presence,Obj***

***Patients,wereStratifiedBasedOn,presenceOfDiseaseAtPresentation,Obj***

***Patients,were,stratified,Obj***

***Patients,wereStratifiedBasedOn,presenceOfMetastaticDiseaseAtPresentation,Obj***

***Patients,wereStratifiedBasedOn,presenceAtPresentation,Obj***

***Patients,wereStratifiedBasedOn,presenceOfDisease,Obj***

***patientDemographics,were,recorded,Obj***

***forty-threeCases,were,analyzed,Obj***

***cases,were,analyzed,Obj***

***follow-up,was,25Months,Obj***

***follow-up,was,25MonthsFromDiagnosis,Obj***

***medianFollow-up,was,25Months,Obj***

***medianFollow-up,was,25MonthsFromDiagnosis,Obj***

***metastaticDisease,withCasesIs,56%,Obj***

***24Cases,isWith,metastaticDiseaseOnPresentation,Obj***

***24ApplicableCases,of13Is,54%,Obj***

***Ulceration,improvedIn,54%,Obj***

***bleeding,improvedFollowing,radiotherapy,Obj***

***bleeding,improvedIn,54%,Obj***

***Ulceration,improvedFollowing,radiotherapy,Obj***

***patients,isWith,LABC,Obj***

***role,isIn,patientsWithLabc,Obj***

***symptomControl,goodResponseIn,mostPatientsInStudy,Obj***

***Radiotherapy,goodResponseIn,patientsInStudy,Obj***

***Radiotherapy,goodResponseIn,mostPatientsInStudy,Obj***

***response,isIn,mostPatients,Obj***

***mostPatients,isIn,study,Obj***

***Radiotherapy,responseIn,patientsInStudy,Obj***

***symptomControl,responseIn,mostPatientsInStudy,Obj***

***Radiotherapy,responseIn,mostPatientsInStudy,Obj***

***symptomControl,responseIn,patientsInStudy,Obj***

***symptomControl,goodResponseIn,patientsInStudy,Obj***

***breastCancer,isRecognizedAs,cancerInPatientsWorldwide,Obj***

***breastCancer,isRecognizedAs,heterogeneousCancerInFemalePatients,Obj***

***breastCancer,is,recognized,Obj***

***heterogeneousCancer,isIn,femalePatientsWorldwide,Obj***

***breastCancer,isRecognizedAs,cancerInPatients,Obj***

***breastCancer,isRecognizedAs,heterogeneousCancerInPatients,Obj***

***breastCancer,isRecognizedAs,cancerInFemalePatients,Obj***

***breastCancer,isRecognizedAs,cancer,Obj***

***breastCancer,isRecognizedAs,heterogeneousCancerInFemalePatientsWorldwide,Obj***

***breastCancer,isRecognizedAs,cancerInFemalePatientsWorldwide,Obj***

***breastCancer,isRecognizedAs,heterogeneousCancer,Obj***

***breastCancer,isRecognizedAs,heterogeneousCancerInPatientsWorldwide,Obj***

***discovery,is,needed,Obj***

***discovery,is,urgentlyNeeded,Obj***

***we,discoveredAccordingTo,ourMolecularBiologyExperimentData,Obj***

***membraneTypeMannoseReceptor,was,highlyExpressed,Obj***

***we,discoveredAccordingTo,ourBiologyExperimentData,Obj***

***we,discoveredAccordingTo,ourPreliminaryBiologyExperimentData,Obj***

***we,discoveredAccordingTo,ourPreliminaryMolecularBiologyExperimentData,Obj***

***membraneTypeMannoseReceptor,wasHighlyExpressedIn,breastCancerPatientsSerum,Obj***

***membraneTypeMannoseReceptor,was,expressed,Obj***

***membraneTypeMannoseReceptor,wasExpressedIn,breastCancerPatientsSerum,Obj***

***membraneTypeMr,be,used,Obj***

***membraneTypeMr,wasExpressedIn,fourTypes,Obj***

***we,assume,differentiallyExpressedInFourTypesOfBreastCancer,Obj***

***we,assume,expressedInFourTypesOfBreastCancer,Obj***

***we,assume,expressed,Obj***

***membraneTypeMr,distinguish,fourTypesOfBreastCancer,Obj***

***membraneTypeMr,wasExpressedIn,fourTypesOfBreastCancer,Obj***

***membraneTypeMr,was,expressed,Obj***

***membraneTypeMr,was,differentiallyExpressed,Obj***

***membraneTypeMr,distinguish,fourTypes,Obj***

***membraneTypeMr,wasDifferentiallyExpressedIn,fourTypes,Obj***

***membraneTypeMr,wasDifferentiallyExpressedIn,fourTypesOfBreastCancer,Obj***

***we,assume,differentiallyExpressed,Obj***

***we,assume,differentiallyExpressedInFourTypes,Obj***

***we,assume,expressedInFourTypes,Obj***

***we,thereforeAnalyzed,glycosylationOfMembraneTypeMr,Obj***

***we,systematicallyAnalyzedGlycosylationBy,massSpectrometry,Obj***

***we,analyzed,glycosylationOfMembraneTypeMr,Obj***

***we,thereforeSystematicallyAnalyzedGlycosylationBy,massSpectrometry,Obj***

***we,thereforeAnalyzedGlycosylationBy,massSpectrometry,Obj***

***we,systematicallyAnalyzed,glycosylationOfMembraneTypeMr,Obj***

***we,analyzed,glycosylation,Obj***

1. ***Report the origin of entities and predicates, example : Entity1 belongs to Abstract 1.***

|  |  |
| --- | --- |
|  |  |
| ***Abstract 1*** | 'We' 'veryrareabnormality' 'patients' 'symptoms' 'include' 'shortnesspalpitationsarrhythmias' 'report' 'onesuchcaseofmanwithdisproportionallyenlargedrightatrium' 'echocardiogram' 'demonstrated' 'hugerightatrium' 'Magneticresonanceimaging' 'confirmedatriomegalywith' 'initialcompressionofventricle' 'patient' 'underwent' 'surgicalresection' 'resectedatrium' 'had' 'normalwallthickness' |
| ***Abstract 2*** | 'driver' 'UnitedStates' 'carcinomas' 'Hereprovide' 'approximately310%' 'observations' 'implicatePTENinactivationas' 'exomesequencing' 'haveuncovered' 'pathogenicaberrationsinhistotype' 'analysis' 'Moreoverresultedin' 'classificationofendometrioidintofoursubgroupsPOLE' 'we' 'discuss' 'potentialimplicationsforcarcinoma' |
| ***Abstract 3*** | 'Toddlersrevisedfollowup' 'aim' 'isknownabout' 'versioninSpanishpublichealthsystem' 'MCHATRF' 'was' 'rightatrium' '15children' 'werediagnosedwith' 'ASD' 'results' 'aresimilarto' 'English' 'study' 'consider' 'ASDscreeningprogram' |
| ***Abstract4*** | 'patients' 'syndrome' 'renaldisease' 'investigate' 'organsystem' 'Neurologicmanifestationin' 'patients' 'Endometrialcancer' 'iswith' 'SLEAAV' 'SAH' 'Neurologicinvolvement' 'present' 'consider' 'associationbetweenSLEAAV' |
| ***Abstract 5*** | 'absenceofeffectivetreatment' 'subtype' 'clinicopathologicalfeatures' 'validate' 'lymphomas' 'poorprognosis' 'isin' 'ModifiedChecklist' 'staging' 'ensure' 'appropriatetreatmentstrategy' |
| ***Abstract 6*** | 'domains' 'spasticataxiaofCharlevoixSaguenayonechildhoodonsetataxias' 'prominentfeature' 'represent' 'manyneuronalpopulations' 'study' 'identifies' 'antineutrophilcytoplasmicvasculitis' 'Peptides' 'encoding' 'ubiquitinlikedomainmodifiedneurofilamentassembly' 'Jdomain' 'had' 'oppositeeffects' |
| ***Abstract 7*** | 'restorativeproctocolectomy' 'Little' 'bundlingin' 'clinicalcharacteristicsofentity' 'NaturalkillerTcelllymphoma' |
| ***Abstract 8*** | 'manifestations' 'relativelyrarebenigntumors' 'Knowledge' 'increasein' 'poor' 'goals' 'describe' 'large520kDamultidomainprotein' 'We' 'performed' 'analysis' 'incidence' 'was' '1.15%amongentireseriesofintracranialCMs' 'theirmeanage' '38.7years' 'manifestation' 'Slowlygrowingwas' 'swelling' 'Completelesionresection' 'achieved' 'symptom' 'resolvedbefore' |
| ***Abstract 8*** | 'petroclivalICM' 'differentialdiagnosis' 'isin' 'caseof' 'Surgicalresection' 'should' 'shouldtreatmentofchoiceforpatients' 'portosystemicshunt' 'livercancer' 'canassociatedwithCAPVS' 'Megapouch' |
| ***Abstract 9*** | 'patient' 'iswith' 'increasingincidence' 'skull' |
| ***Abstract 10*** | 'purpose' 'hasconsidered' 'causes' 'portalperfusion' |
| ***Abstract 11*** | 'trichothiodystrophy' 'groupofdiseasescharacterizedbyDNArepairanomalies' 'Ocularmanifestations' 'canoccurin' '50%ofcasesincludingcataracterrors' 'patient' 'iswith' 'Recentstudies' |
| ***Abstract 12*** | 'Magneticresonanceangiography' 'cord' 'arisingin' 'levelwithdiscretehistopathology' 'We' 'report' 'twocases' 'Acuteretinitis' 'demonstrated' 'severestenosisofterminalportionofbilateralcarotidarteries' 'CranialMRimages' 'showed' 'hematomainbasalgangliaperforating' 'patient' 'underwentremovalAfter' 'conservativemanagement' 'tumor' 'consistedof' |
| ***Abstract 13*** | 'components' 'extracomponents' 'were' 'schwannomarespectively' 'CraniocervicalMRimages' 'majorextradural' 'extradurallesion' 'was' 'meningioma' 'be' 'shouldconsideredintumors' |
| ***Abstract 14*** | 'havealreadyimplicatedinkeyprocessesofSSc' 'connectivetissuedisease' 'CCNproteins' 'ofonehalfis' 'proteins' 'They' 'have' 'Trichothiodystrophy' 'we' 'discuss' 'possibleimplicationinSScpathogenesiswithfocusonskinfeatures' 'article' 'protected' |
| ***Abstract 15*** | 'patient' 'commonadultintraocularcancer' 'livermetastasis' 'commontonaturalhistoryofdiseasemetastasistoeye' 'we' 'Herereport' 'case' 'tumors' 'was' 'referred' 'He' 'have' 'newpigmentedtumor' 'ultrasonography' 'were' 'performed' 'similarcases' 'havedescribed' 'differentialdiagnosis' 'included' 'choroidaltumor' |
| ***Abstract 16*** | 'surgery' 'changes' 'granulocytes' 'arefamilyof' 'sepsis' 'infections' 'arecomplicationof' 'sclerosis' 'frontlineclinician' 'assessmentwith' 'multicolorflowcytometry' |
| ***Abstract 17*** | 'bonetumors' 'purpose' 'analyze' 'outcomesofpatientswithadamantinoma' 'Uvealmelanoma' |
| ***Abstract 18*** | 'diseaseonset' 'bonedisorder' 'PPRD' 'radiologicalfeatures' 'clinicallaboratoryof' 'isdueto' 'mutation' 'sepsissurgery' 'progressesover' 'timeleading' |
| ***Abstract 19*** | 'child' 'developsinvolvementwithout' 'systemicinflammation' 'Genetictesting' 'shouldstartwith' 'studyofgenomicDNA' 'patients' 'iswith' 'typicalPPRDfindings' |
| ***Abstract 20*** | 'we' 'predominates' 'characterizationfromDPV' 'Adamantinomas' |

1. ***Report common and unique entities and predications among the Topics / Abstracts***

***{ Make sure the comparison is meaningful }***

**Submission Guidelines (for all students):**

1. Submit your source code to GitHub.
2. Submit your documentation (submit your screenshots as well. The screenshot should have both the code and the output) to your Turnitin.
3. Comment your code appropriately.
4. Use the following google link to submit your assignment

(Lab Submission Link#) : https://goo.gl/forms/MP2n7LQGmm2atsZo2

***Cheating, plagiarism, disruptive behavior and other forms of unacceptable conduct are subject to strong sanctions in accordance with university policy. See detailed description of university policy at the following URL:*** [*https://catalog.umkc.edu/special-notices/academic-honesty/*](https://catalog.umkc.edu/special-notices/academic-honesty/)